Superluminal Medicines combines agentic cryo-EM structure determination, protein-dynamics simulation and machine learning to design small molecules against G protein-coupled receptors, screening for functional selectivity at scale. Its lead program is a selective, biased MC4R agonist for rare genetic and hypothalamic obesity, with Phase 1 targeted by end of 2026.